ArticleFrontiers in oncology2021
Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Comparing efficacy of charged-particle therapy with brachytherapy in treatment of uveal melanoma.Eye (London, England) · 2024Pooled it
- Review
- Article
- The Small Choroidal Melanoma: Diagnosis, Treatment Outcomes, and Unending Controversy.Seminars in ophthalmology · 2025Review
- Clinical outcomes and risk factors for local failure and visual impairment in patients treated with Ru-106 brachytherapy for uveal melanoma.Clinical and translational radiation oncology · 2025Article
- Platinum group metals for nuclear medicine, a luxurious dream or the future of imaging and therapy: a review.Frontiers in nuclear medicine · 2025Review
- A cohort of long-surviving patients affected by small and medium uveal melanoma treated with ruthenium-106 plaque brachytherapy.Contemporary oncology (Poznan, Poland) · 2024Article
- A prognostic nomogram for the cancer-specific survival rate of choroidal melanoma using the Surveillance, Epidemiology, and End Results database.Frontiers in medicine · 2024Article
- Subconjunctival Ocular Argyrosis following Treatment with Ruthenium 106 Brachytherapy for Choroidal Melanoma.Ocular oncology and pathology · 2023Article
- Radiotherapy in Uveal Melanoma: A Review of Ocular Complications.Current oncology (Toronto, Ont.) · 2023Review
- Deterioration of Visual Acuity after Brachytherapy and Proton Therapy of Uveal Melanoma, and Methods of Counteracting This Complication Based on Recent Publications.Medicina (Kaunas, Lithuania) · 2023Review
- Outcome of Ruthenium-106 Brachytherapy for Uveal Melanoma and Retinal Vascular Tumors: A Retrospective Study.Journal of current ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uveal melanoma is the most common primary intraocular malignancy. The aim of this retrospective study was to report the results after ruthenium-106 (Ru-106) plaque brachytherapy for uveal melanoma in terms of tumor control, visual acuity, radiation-related complications, tumor recurrence, metastases, and patients' survival rate during 4 years' follow-up. A total of 355 eyes from 355 patients have been treated with Ru-106 plaque brachytherapy for uveal melanoma between February 2011 and March 2020. Five patients were lost to follow-up, and then 350 eyes of 350 patients (mean age 58 ± 11 years) were enrolled in this retrospective study. All patients underwent a complete ophthalmic examination including echography and spectral domain-optical coherence tomography. The mean follow-up was 4 years (3 months to 9 years). After treatment, the mean tumor thickness was reduced to 1.75 ± 0.21 mm. Radiation complications were found in 63% of patients: 38% showed radiation maculopathy, 11% had optic neuropathy, and 14% developed cataracts. Cancer-free survival was 99%, 97%, and 85%, respectively, at 5, 7, and 9 years. Ru-106 plaque brachytherapy represents a reliable treatment of uveal melanoma. This technique is valid and safe with a low rate of ocular complications during a long-term follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.